Full Press Release Details
IDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ.
IDYA
IDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ
Key Takeaway: IDEAYA Biosciences and Boston Childrens Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome a Rare Disease Associated with Genetic Mutation of GNAQ
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma